Unlike estrogen receptor-positive (ER( þ )) breast cancers, normal human mammary epithelial cells (HMECs) typically express low nuclear levels of ER (ER poor). We previously demonstrated that 1.0 lM tamoxifen (Tam) promotes apoptosis in acutely damaged ER-poor HMECs through a rapid, 'nonclassic' signaling pathway. Interferon-regulatory factor-1 (IRF-1), a target of signal transducer and activator of transcription-1 transcriptional regulation, has been shown to promote apoptosis following DNA damage. Here we show that 1.0 lM Tam promotes apoptosis in acutely damaged ER-poor HMECs through IRF-1 induction and caspase-1/3 activation. Treatment of acutely damaged HMEC-E6 cells with 1.0 lM Tam resulted in recruitment of CBP to the c-IFN-activated sequence element of the IRF-1 promoter, induction of IRF-1, and sequential activation of caspase-1 and -3. The effects of Tam were blocked by expression of siRNA directed against IRF-1 and caspase-1 inhibitors. These data indicate that Tam induces apoptosis in HMEC-E6 cells through a novel IRF-1-mediated signaling pathway that results in activated caspase-1 and -3.
Introduction
The 'classic' or genomic mechanism of b-estradiol (E2) action requires the presence of the estrogen receptor (ER), the E2/ER complex binding to an ERE, and changes in both transcription and translation. However, recent evidence suggests that estrogen and perhaps antiestrogens may also act through rapid, 'nonclassic' signaling pathways in mammary epithelial cells (Kelly and Levin, 2001) . Tamoxifen (Tam) is an ER agonist/ antagonist that has been characterized as an inhibitor of the classic E2 pathway. The Breast Cancer Prevention Trial demonstrated a decreased incidence of in situ and ER( þ ) breast cancer in the high-risk participants who were prescribed Tam for 5 years (Fisher et al., 1998) . However, the molecular mechanism of Tam action in normal breast tissue is poorly understood. Normal human mammary epithelial cells (HMECs), unlike ER( þ ) breast cancers, typically express low nuclear levels of ER (ER poor) (Anderson et al., 1998) . As a result, it is uncertain whether Tam is able to target the elimination of acutely damaged, ER-poor cells or whether Tam's action is restricted to mammary epithelial cells that express high levels of ER. We have previously shown that 1.0 mM Tam rapidly promotes apoptosis in acutely damaged, ER-poor HMECs but only induces growth arrest in HMEC controls Seewaldt et al., 2001 ). Here we further investigated the molecular mechanism of Tam-induced apoptosis in acutely damaged HMECs. Acute cellular damage was modeled via expression of the human papilloma virus (HPV) E6 protein (E6), which results in dysregulation of multiple signaling pathways crucial for cellular homeostasis. E6 protein affects these pathways by interacting with proteins such as p53, p300/CBP, Bak, IRF-3, and paxillin and provides a convenient model of acute cellular damage (Mantovani and Banks, 2001) .
Interferons (IFNs) are a family of cytokines that have multiple biological effects including immunomodulatory, antiviral, antiproliferative, antigen modulation, cell differentiation, and apoptotic effects (Pestka et al., 1987; Stark et al., 1998; Chawla-Sarkar et al., 2003) . Upon secretion from cells, IFNs bind to specific cell membrane receptors and activate the JAK-STAT pathway, which results in upregulation of IFN-stimulated genes (ISGs) (Darnell et al., 1994; Stark et al., 1998) . Many of the biological effects from IFNs are mediated by these ISGs.
IFNs have also been shown to enhance the growth inhibitory actions of Tam (Gibson et al., 1993; Coradini et al., 1997; Iacopino et al., 1997) . In studies by Lindner et al., treatment with Tam (1.0 mM) and IFN-b (100 IU/ ml) resulted in growth inhibition in both ER( þ ) and ER(À) breast cancer cell lines. In ER(À) cell lines, Tam in combination with IFN-b treatment was significantly more effective in inhibiting cell growth than Tam alone. In addition, in MCF-7 cells resistant to IFN-b treatment, preincubation with Tam followed by IFN-b treatment resulted in growth inhibition and upregulation of the ISGs 2 0 -5 0 -oligoadenylate synthetase, PKR, and IFN-induced protein (IFI) 56. Furthermore, in vivo studies using nude mice with established 6-week-old MCF-7 (ER( þ )) and OVCAR-3 (ER(À)) breast tumors showed tumor regression only with combined Tam/IFN therapy . This synergistic cytotoxicity, combined with the observed induction of IFN genes in IFN-resistant cells, suggests possible cross-talk between the two pathways. Cross-talk with the IFN pathway has also been shown with other steroid/thyroid and death receptor modulators including retinoic acid (Kolla et al., 1996) and TRAIL/APO-2L (Kumar-Sinha et al., 2002) .
ISGs exert their effects in many different ways, including promoting apoptosis. Signal transducer and activator of transcription-1 (STAT1) is activated upon IFN ligand binding to its receptor, and acts either in a complex with STAT2/p48 (ISGF3), or as a homodimer, to induce transcription of ISGs (Horvath, 2000) . IFNregulatory factor-1 (IRF-1) is a target of STAT1 transcriptional regulation (Pine et al., 1994) . IRF-1 itself transcriptionally regulates additional ISGs and has been shown to promote apoptosis following DNA damage (Tanaka et al., 1994; Tamura et al., 1995; Henderson et al., 1997) . Specifically, IRF-1 promotes apoptosis associated with caspase-1 activation (Tamura et al., 1995; Romeo et al., 2002) . More recently, IRF-1 has been shown to be a tumor suppressor and critical for mammary gland involution (Yim et al., 1997; Nozawa et al., 1999; Hoshiya et al., 2003; Kim et al., 2004) . Studies have also shown that IRF-1 expression is lowered or the gene is mutated in multiple cancers, including breast cancer (Doherty et al., 2001; Tzoanopoulos et al., 2002) .
CREB-binding protein (CBP) has been shown to be a critical coactivator in IFN signaling (Horvai et al., 1997; Merika et al., 1998) . CBP, located at chromosome band 16p13.3, is a transcriptional cofactor that regulates proliferation, differentiation, and apoptosis (Giles et al., 1997b; Yao et al., 1998) . Chromosomal loss at 16p13 has been reported to occur in a majority of benign and malignant papillary neoplasms of the breast and loss or amplification of 16p is frequently observed in premalignant breast lesions (Lininger et al., 1998; Tsuda et al., 1998; Aubele et al., 2000) . CBP acts as a key integrator of diverse signaling pathways including those regulated by retinoids, p53, and estrogen, and has been hypothesized to play a role in BRCA1-mediated DNA repair (Kawasaki et al., 1998; Robyr et al., 2000) . CBP levels are tightly controlled and CBP is thought to be present in limiting amounts. It has been theorized that the many transcription factors requiring CBP compete for its binding (Giles et al., 1997a; Kawasaki et al., 1998; Yao et al., 1998; Robyr et al., 2000) . Recent evidence indicates that CBP activity is also regulated by both phosphorylation and expression (Guo et al., 2001) .
In this study, we aimed to identify potential mediators of Tam-induced apoptosis in acutely damaged HMEC apoptosis-sensitive cells expressing E6. Here we show that Tam promotes apoptosis in acutely damaged HMEC-E6 cells through IRF-1 induction and caspase-1 activation. These results provide evidence for a novel role for ISG signaling in targeting the elimination of acutely damaged HMECs.
Results

cDNA microarray analysis of Tam-induced gene transcripts
To investigate the molecular mechanism of Taminduced apoptosis, we analysed the expression profiles of acutely damaged HMEC-E6 cells and passagematched HMEC-LX controls treated with or without 1.0 mM Tam for 6 h. Analysis was performed using Hu6800 cDNA microarrays (Affymetrixt). As shown in Table 1 , 20 ISGs were significantly upregulated in Tamtreated HMEC-E6 cells but not in HMEC-LX controls. The upregulated genes included (fold change >1.5; P-value o0.05) IFI9-27, IRF-1, ISG15, ISG-54, MX-A, IFN-g inducible protein 16, STAT1 a, STAT1 b, IFI 6-16, and ISG12. Differential expression was confirmed by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in triplicate, and normalized to b-actin (Figure 1 ). Based on these observations, we hypothesized that ISGs may (1) participate in or (2) be a marker for Tam-induced apoptosis in acutely damaged HMEC-E6 cells. 
IRF-1 is induced by Tam
IRF-1 is a transcriptional regulator that has been shown to promote apoptosis following DNA damage and is critical for mammary gland involution (Kroger et al., 2002; Hoshiya et al., 2003 (Figure 2a and b). IRF-1 protein induction was first observed at 30 min (1.5-fold, P-value o0.025) and was maximally induced at 3 h (2.3-fold, P-value o0.001) (Figure 2c and d). These observations demonstrate that IRF-1 mRNA and protein are induced by Tam in acutely damaged HMEC-E6 cells starting at 30 min.
Tam promotes recruitment of CBP to the IFN consensus sequence 2/g-IFN-activated sequence (ICS2/GAS) element of the IRF-1 promoter Chromatin immunoprecipitation (ChIP) and immunoprecipitation studies were performed to identify coactivators that might participate in IRF-1 mRNA induction in apoptosis-sensitive HMEC-E6 cells. CBP is a known regulator of apoptosis and a coactivator for steroid/ thyroid and type II IFN signaling (Horvai et al., 1997; Hiroi and Ohmori, 2003) . STAT1 is a transcriptional regulator of IRF-1 and has been shown to interact with CBP through the (1) CREB-binding domain and (2) CH3 domain (Zhang et al., 1996) . Recently, an IFNinducible GAS element was identified in the IRF-1 promoter that serves to activate IRF-1 transcription (Sims et al., 1993; Harada et al., 1994) . Using ChIP and immunoprecipitation studies, we tested whether Tam treatment of HMEC-E6 cells may promote (1) CBP or STAT1 recruitment to this IRF-1 promoter GAS element and (2) induction of IRF-1 mRNA expression at 0, 2, and 6 h. We observed that STAT1 was constitutively associated with the GAS element of the IRF-1 promoter in HMEC-E6 cells and Tam treatment did not alter this association (Figure 3a) . In contrast, CBP was recruited to the IRF-1 promoter 2 h following treatment of HMEC-E6 cells with 1.0 mM Tam (Figure 3a) . Neither STAT1 nor CBP were recruited to the GAS element of the IRF-1 promoter in HMEC-LX controls with Tam treatment (data not shown). The observation that STAT1 was constitutively bound to the IRF-1 GAS element in the HMEC-E6 cells suggested that it may be active at baseline. There are two known phosphorylation sites within STAT1, Tyr701 and Ser727. It has been shown that phosphorylation of Ser727 induces the highest transcriptional activation for STAT1 (Wen et al., 1995) . Western analysis was performed to determine the phosphorylation status of STAT1 in the untreated acutely damaged HMEC-E6 cells. We observed that STAT1 is phosphorylated at Ser727 in the HMEC-E6 cells at baseline (Figure 4d ). The activation of STAT1 in the HMEC-E6 cells at baseline may be a response to the expression of E6 in these cells.
An immunoprecipitation time course using a biotinlabeled oligo, containing the IRF-1 GAS promoter element, was performed to precisely pinpoint the temporal correlation between (1) CBP recruitment to the IRF-1 promoter and (2) IRF-1 mRNA induction in Tam-treated HMEC-E6 cells. CBP was recruited to the GAS element of the IRF-1 promoter at 30 min after 1.0 mM Tam treatment ( Figure 3b ). STAT1 was again shown to be constitutively associated with the IRF-1 promoter GAS element between 0 and 60 min (data not shown). CBP recruitment correlated with IRF-1 mRNA induction at 30 min ( Figure 2 ). These observations demonstrate that Tam-mediated recruitment of CBP to the GAS element of the IRF-1 promoter in acutely damaged HMEC-E6 cells is temporally concurrent with IRF-1 mRNA and protein induction.
IFI 6-16 is induced by Tam
IFNs have been shown to regulate the expression of the IFI 6-16 gene (Gjermandsen et al., 2000) . Specifically, IRF-1 expression induces transcription of IFI 6-16 (Henderson et al., 1997) . Our differential gene expression studies demonstrate that IFI 6-16 mRNA is ChIP was performed to test for STAT1 and CBP recruitment to the IRF-1 GAS element as a function of Tam treatment. Early passage acutely damaged HMEC-E6 cells (passage 11) were treated with 1.0 mM Tam for 0, 2, and 6 h as described in Materials and methods. Input controls tested the integrity of the DNA samples. These data represent three separate experiments. (b) An immunoprecipitation time course using a biotin-labeled oligo, containing the IRF-1 GAS promoter element, was performed to investigate the temporal correlation between CBP recruitment to the IRF-1 promoter and IRF-1 mRNA induction in Tam treated early passage HMEC-E6 cells (passage 12) as described in Materials and methods. CBPinput controls are provided to assess the CBP content of protein lysates subjected to immunoprecipitation. CBP-bound assesses the amount of CBP bound to the IRF-1 GAS promoter element oligo. These data are representative of three separate experiments induced by treatment of acutely damaged HMEC-E6 cells with 1.0 mM Tam for 6 h. Semiquantitative RT-PCR was performed to determine the kinetics of IFI 6-16 mRNA induction. IFI 6-16 mRNA was induced by 1.0 mM Tam in acutely damaged HMEC-E6 cells but not in HMEC-LX controls (Figure 4) . Induction of IFI 6-16 mRNA was (1) first observed in HMEC-E6 cells by 2 h, (2) statistically significant by 3 h (2.2-fold), and (3) maximally induced at 6 h (3.1-fold) ( Figure 4a ). These observations demonstrate that Tam induces IFI 6-16 mRNA in acutely damaged HMEC-E6 cells starting at 3 h.
Tam promotes recruitment of IRF-1, STAT1, and CBP to the IFI 6-16 promoter IFN-stimulated response element (ISRE) element IRF-1 has been shown to complex with STAT1 and to induce ISG expression through binding to the ICS2/ GAS element (Chatterjee-Kishore et al., 1998). In addition, IRF-1 has been shown to directly bind to the ISRE within the IFI 6-16 promoter and induce transcription (Parrington et al., 1993) . We observe induction of IFI 6-16 mRNA in HMEC-E6 cells by 3 h after treatment with 1.0 mM Tam. ChIP was performed to test whether recruitment of IRF-1, STAT1, and the coactivator CBP to the ISRE element of the IFI 6-16 promoter temporally correlated with IFI 6-16 mRNA induction. We observed that IRF-1, STAT1, and CBP are simultaneously recruited to the ISRE element of the IFI 6-16 promoter in acutely damaged HMEC-E6 cells after 2 h treatment with 1.0 mM Tam (Figure 4c ). These observations demonstrate that Tam treatment of acutely damaged HMEC-E6 cells promotes recruitment of IRF-1, STAT1, and CBP to the IFI 6-16 promoter at 2 h, followed by induction of IFI 6-16 mRNA by 3 h.
Caspase-1 and -3 are induced by Tam
IRF-1 is thought to mediate apoptosis through activation of caspase-1 (Karlsen et al., 2000; Kim et al., 2002) . Recently, overexpression of IRF-1 in two mouse breast cancer cell lines has also shown to activate caspase-3 (Kim et al., 2004) . We have previously shown that caspase-3 is activated by 1.0 mM Tam in acutely damaged HMEC-E6 cells starting at 6 h, maximally at 24 h, and precedes the appearance of marginated chromatin (early effector-phase apoptosis), first observed at 12 h . In contrast, we observed that caspase-3 was not activated by Tam in HMEC-LX controls ).
Here we tested for caspase-1 activation in Tamtreated acutely damaged HMEC-E6 cells and HMEC-LX controls. Our gene chip data showed no increase in caspase-1 mRNA at 6 h, in either the HMEC-LX controls or the HMEC-E6 cells (data not shown). In HMEC-E6 cells, however, caspase-1 was activated by 1.0 mM Tam starting at 3 h (Figure 5a ). This activation temporally correlated with maximal IRF-1 mRNA and protein induction observed at 2-3 h (Figure 2 ). In contrast, caspase-1 was not activated in passagematched HMEC-LX controls (Figure 5a ).
Caspase-1 inhibitor IV blocks Tam-induced apoptosis
HMEC-E6 cells were pretreated with caspase-1 inhibitor IV to test whether caspase-1 activation was required for Tam (Figure 5d ). Caspase-1 inhibitor IV treatment alone did not alter the proliferation rate of HMEC-E6 cells and did not induce apoptosis (Figure 5d and data not shown). These data demonstrate that caspase-1 activation is required for Tam-induced apoptosis in acutely damaged HMEC-E6 cells.
siRNA directed against IRF-1 blocks Tam-induced activation of caspase-1/3 and apoptosis siRNA was used to test whether suppression of IRF-1 expression blocked Tam-mediated caspase activation and apoptosis in acutely damaged HMEC-E6 cells. Treatment of HMEC-E6 cells with siRNAs IRF-1 #1 and IRF-1 #4 sequences for 12 h resulted in suppression of IRF-1 protein and mRNA (Figure 6a and data not shown). We observed that 1.0 mM Tam activated caspase-1 at 3-4 h (Figure 5a ). Suppression of IRF-1 expression in HMEC-E6 cells by IRF-1-specific siRNA blocked Tam-mediated caspase-1 activation at 3 and 4 h (Figure 6b ). We previously demonstrated that caspase-3 is activated by 1.0 mM Tam in acutely damaged HMEC-E6 cells starting at 6 h and maximally at 24 h . Suppression of IRF-1 expression in HMEC-E6 cells by IRF-1-specific siRNA blocked Tam-mediated caspase-3 activation at 12 h (Figure 6c ). In previously published data, we showed that 1.0 mM Tam induced apoptosis in acutely damaged HMEC-E6 cells as demonstrated by Annexin V binding at 18 h ). Here we show that two siRNA sequences directed against IRF-1 blocked Tammediated apoptosis in HMEC-E6 cells (Figure 6d ). These observations demonstrate that IRF-1 expression is required for Tam-induced caspase-1/3 activation and apoptosis in acutely damaged HMEC-E6 cells. 
Discussion
While IFN signaling is important for eliminating cells that are damaged by viral infection, evidence suggests that IFN signaling, through STAT1, IRF-1, and other ISGs, may play a more comprehensive role in mammary gland homeostasis and response to DNA damage. Recently, a similar subset of IFN-regulated genes was induced by overexpression of BRCA1, in the absence of further IFN production (Andrews et al., 2002) . This observation suggests that the loss of BRCA1 may facilitate the disruption of the IFN response. IFNregulatory proteins such as IRF-1, STAT1, and ISG12 are dysregulated during breast carcinogenesis (Rasmussen et al., 1993; Watson and Miller, 1995; Doherty et al., 2001 ) and IFN exhibits cross-talk with estrogen and retinoid signaling (Kolla et al., 1996; Widschwendter et al., 1996; Bjornstrom and Sjoberg, 2002) .
Here we report a novel role for the ISG, IRF-1, in regulating Tam-mediated apoptosis in acutely damaged HMEC-E6 cells. This finding is not completely unexpected. Recent reports have highlighted the ability of IRF-1 to mediate growth arrest and apoptosis in breast cancer cell lines (Kim et al., 2002 (Kim et al., , 2004 Hoshiya et al., 2003) . In addition, evidence suggests that IRF-1 plays a role in mammary homeostasis, as IRF-1 is critical for mammary gland involution and loss of expression of IRF-1 is an early event in mammary carcinogenesis (Doherty et al., 2001) . In this study, IRF-1 expression was induced by 60 min treatment with 1.0 mM Tam (Figure 2 ). IRF-1 was induced by Tam in acutely damaged HMEC-E6 cells 1-3 h prior to subsequent ISG induction, 9 h prior to caspase-3 induction, and 21 h prior to late effector-phase apoptosis (detection of apoptotic bodies) (Figure 2 and data not shown). Suppression of IRF-1 expression by siRNA sequences blocked the induction of apoptosis by Tam (Figure 6 ). Recently, an IFN-inducible GAS element has been identified in the IRF-1 promoter (Sims et al., 1993; Harada et al., 1994) . STAT1 homodimers bind to this GAS element and induce transcription. At a similar IFN response element, called gRE element, a STAT1 dimer binds and recruits CBP to the promoter complex (Hiroi and Ohmori, 2003) . STAT1 has been shown to interact with CBP through both the CREB-binding domain and CH3 domain (Zhang et al., 1996) . IRF-1 in turn has been reported to complex with STAT1 to induce ISG expression by binding to the ICS2/GAS element (Chatterjee-Kishore et al., 1998). Based on these observations we hypothesized that (1) STAT1 and CBP may play a role in IRF-1 induction and (2) IRF-1/ STAT1/CBP, in turn, may cooperatively promote induction of further ISGs.
ChIP and immunoprecipitation experiments demonstrated that STAT1 was constitutively bound to the GAS element of the IRF-1 promoter in HMEC-E6 cells (Figure 3 ). In contrast, CBP was not associated with the IRF-1 GAS element at baseline. ChIP and immunoprecipitation experiments demonstrated that CBP was recruited to the GAS element of the IRF-1 promoter by 30 min after Tam treatment (Figure 3) . Neither STAT1 nor CBP were associated at baseline or recruited to the IRF-1 GAS element in HMEC-LX vector control cells. Based on these observations, we hypothesize that CBP recruitment to the IRF-1 GAS element may be the crucial step in upregulation of IRF-1 mRNA following Tam treatment.
Induction of IRF-1 was closely followed by induction of a small set of ISGs (Table 1) . IRF-1 has previously been shown to participate in the induction of the ISG, IFI 6-16, through recruitment of IRF-1 to the IFI 6-16 promoter ISRE sequence (Parrington et al., 1993) . Here we report that induction of IFI 6-16 mRNA temporally correlated with recruitment of STAT1, IRF-1, and CBP to the ISRE of the IFI 6-16 promoter region (Figure 4) . Tam induced IFI 6-16 mRNA expression at 3 h in acutely damaged HMEC-E6 cells but not in HMEC-LX controls (Table 1, Figures 1 and 4) . ChIP analysis of untreated HMEC-E6 cells showed that IRF-1, STAT1, and CBP were not bound to the IFI 6-16 ISRE at baseline (Figure 4c ). However, when acutely damaged HMEC-E6 cells were treated with 1.0 mM Tam for 2 h, IRF-1, CBP, and STAT1 were recruited to the ISRE sequence in the IFI 6-16 promoter (Figure 4 ) and this recruitment was followed by the induction of IFI 6-16 mRNA at 3 h. These observations demonstrate a potential role for Tam (1) in promoting IRF-1 recruitment to the IFI 6-16 promoter and (2) perhaps in promoting IFI 6-16 mRNA expression. Work is ongoing in our laboratory to define (1) the requirement for IRF-1/STAT1/CBP in modulating IFI 6-16 expression and (2) whether IFI 6-16 directly participates in Taminduced apoptosis in acutely damaged HMEC-E6 cells or whether it serves only as a marker of IRF-1 induction.
Caspase-1 and -3 have previously been shown to participate in IRF-1-mediated apoptosis (Kim et al., 2002 (Kim et al., , 2004 . IRF-1 has been shown to be critical for caspase-1 mRNA induction from cytokine treatment (Karlsen et al., 2000) . While caspase-3 is clearly an effector caspase, the role of caspase-1 in promoting effector-phase apoptosis is controversial. Caspase-1/ICE is traditionally considered an initiator caspase, well known for its inflammatory actions in activating both IL-1b and IL-18 cytokines (Creagh et al., 2003) . Some earlier studies, however, suggest that it is also involved in apoptosis (Miura et al., 1993; Wang et al., 1994) . There have also been several reports of sequential activation of caspase-1 and -3 (Kamada et al., 1997; Dai and Krantz, 1999; Pasinelli et al., 2000; AibaMasago et al., 2001; Zhang et al., 2003; Jiang et al., 2004) . While the phenotype of the caspase-1 knockout mouse did not show major dysregulation of apoptosis, ICE(À/À) thymocytes were resistant to Fas-mediated apoptosis (Kuida et al., 1995) . More recently, studies with IFN-g have shown that caspase-1 is induced and activated in cells sensitive to apoptosis (Detjen et al., 2001 (Detjen et al., , 2002 Kim et al., 2002) .
Here we observed that caspase-1/3 are activated by Tam in acutely damaged HMEC-E6 cells by 3 and 12 h ( Figure 5 , Dietze et al., 2001) , respectively, in the absence of IFN secretion (data not shown). Microarray analysis for both HMEC-LX and HMEC-E6 cells showed no induction of caspase-1 mRNA at 6 h (data not shown), however, caspase-1 was activated 2 h after the observed increase in IRF-1 protein levels (Figure 5a ). Inhibition of caspase-1 activity with 15 nM caspase-1 inhibitor IV blocked Tam-induced (1) activation of caspase-1 and -3 and (2) effector-phase apoptosis ( Figure 5 ). siRNA directed against IRF-1 also blocked Tam-mediated activation of caspase-1/3 and apoptosis ( Figure 6 ). Taken together these data indicate that Taminduced apoptosis in acutely damaged HMEC-E6 cells requires both induction of IRF-1 and a subsequent increase in caspase-1 activity.
We have previously shown that caspase-9 was induced by Tam treatment of HMEC-E6 cells (Dietze et al., , 2004 . Caspase-9 induction occurred within 1 h of Tam treatment and returned to baseline by 12 h after Tam treatment . Caspase-9 has not been shown to process procaspase-1. Thus it is unlikely that caspase-9 is involved in the observed activation of caspase-1. Also, IRF-1(À/À) cells were still able to induce caspase-9 activity (Oda et al., 2000) . Taken together with the kinetics of IFI 6-16 induction (Figure 4) , it is unlikely that IRF-1 participates in caspase-9 activation. The exact relationship of caspase-9, -1, and -3 to each other and to the execution phase of apoptosis is under study in our laboratory.
In previously published studies, we have recently shown that Tam treatment of acutely damaged HMEC-E6 cells results in rapid loss of AKT Ser-473 phosphorylation and activity (Dietze et al., 2004) . In this report we demonstrate that (1) Tam promotes recruitment of CBP to the GAS element of the IRF-1 promoter and (2) this recruitment is temporally associated with induction of IRF-1. It is known that CBP and its related coactivator, p300, are present in limiting amounts. The current paradigm of CBP/p300 action suggests that CBP/p300 activity is mediated by competition of various promoter elements for limited quantities of CBP/p300. However, recent studies suggest that the activity of CBP may also be controlled by phosphorylation, although correlation between specific sites of phosphorylation and alteration of function has been rare (Kovacs et al., 2003) . Given our recent observations regarding (1) the role of AKT in regulating Tam-induced apoptosis and (2) Tam-modulated CBP recruitment to the IRF-1 GAS element, we are currently investigating the potential role of AKT in promoting CBP recruitment and IRF-1 induction. AKT has been shown to phosphorylate the CBP analog p300 in the CH3 domain and block the transcriptional activity of C/EBPb, which binds that domain (Guo et al., 2001) . We are currently investigating the possibility that AKT functions in a similar fashion to promote CBP binding to the STAT1-bound IRF-1 GAS element and thereby promote IRF-1 transcription in acutely damaged HMEC-E6 cells.
Materials and methods
Materials
All chemicals and cell culture reagents were obtained from Sigma-Aldrich (St Louis, MO, USA), DNA primers from Invitrogen (Carlsbad, CA, USA) or Qiagen Operon (Alameda, CA, USA), and cell culture plasticware from Corning (Corning, NY, USA) unless otherwise noted. A 1.0 mM stock solution of Tam was prepared in 100% ethanol and stored in opaque tubes at À701C. Control cultures received equivalent volumes of the ethanol solvent. Stocks were used under reduced light. Caspase-1 inhibitor IV was obtained from EMD Biosciences Inc. (San Diego, CA, USA). IFN-g was obtained from R&D Systems (Minneapolis, MN, USA), reconstituted to a 10 mg/ml stock with 1 Â PBS (0.1% BSA), and stored at À701C.
Cell culture and media
Normal HMEC strain AG11132 (M Stampfer #172R/AA7) was purchased from the National Institute of Aging, Cell Culture Repository (Coriell Institute, Camden, NJ, USA; Stampfer, 1985) . HMEC strain AG11132 was established from normal tissue obtained at reduction mammoplasty, has a limited life span in culture, and fails to divide after approximately 20-25 passages. HMECs exhibit a low level of ER staining characteristic of normal mammary epithelial cells. HMECs were grown in mammary epithelial cell basal medium (Clonetics, San Diego, CA, USA) supplemented with 4 ml/ml bovine pituitary extract (Clonetics #CC4009), 5 mg/ml insulin (UBI, Lake Placid, NY, USA), 10 ng/ml epidermal growth factor (UBI), 0.5 mg/ml hydrocortisone, 10 À5 M isoproterenol, and 10 mM HEPES buffer (Standard Media). G418 containing Standard Media was prepared by the addition of 300 mg/ml of G418 (Gibco, Grand Island, NY, USA) to Standard Media. Cells were cultured at 371C in a humidified incubator with 5% CO 2 /95% air. Mycoplasma testing was performed as previously reported (Seewaldt et al., 1997a) .
Retroviral transduction
The LXSN16E6 retroviral vector containing the HPV-16 E6 coding sequence was provided by D Galloway (Fred Hutchinson Cancer Research Center, Seattle, WA, USA) (Demers et al., 1996) . HMECs (passage 9) were plated in four T-75 tissue culture flasks in standard medium and grown to 50% confluency. Transducing virions from either the PA317-LXSN16E6 or the control PA317-LXSN (without insert) retroviral producer line were added at a multiplicity of infection at 1 : 1 in the presence of 4 mg/ml polybrene to logphase cells grown in T-75 flasks. The two remaining T-75 flasks were not infected with virus. After 48 h two flasks containing transduced cells and one flask with untransduced cells were passaged 1 : 3 (passage 10) and selected with standard media containing 300 mg/ml G418. Cells were grown in G418 containing standard media for 4-7 days, until 100% of control untransduced cells were dead. The transduction efficiency was high during selection, cells were passaged 1 : 3 at the completion of selection (passage 11), and cells were maintained in the absence of selection before immediately proceeding to apoptosis experiments. The fourth flask of unselected, untransduced parental control cells was passaged in parallel with the selected, transduced experimental and vector control cells. Parental AG11132 cells were designated HMEC-P. Transduced AG11132 cells expressing the HPV-16 E6 construct were designated HMEC-E6 and vector control clones were designated HMEC-LX. All cells were maintained in standard media after transfection in the absence of G418 selection to ensure that any observed chromosomal abnormalities or apoptosis resistance was not due to continued exposure to G418. All experiments were performed on mass cultures.
Differential gene expression studies
Total RNA isolation was as previously described (Seewaldt et al., 1995) . RNA integrity was confirmed by electrophoresis, and samples were stored at À701C until used. All RNA combinations used for array analysis were obtained from cells that were matched for passage number, cultured under the identical growth conditions, and harvested at identical confluency. cDNA synthesis and probe generation for cDNA array hybridization were obtained by following the standardized protocols provided by Affymetrix (Affymetrix, Santa Clara, CA, USA).
Expression data for approximately 5600 full-length human genes were collected using Affymetrix GeneChip HuGeneFLt arrays, and following the standardized protocols provided by the manufacturer. Data were collected in triplicate using independent biological replicates. Array images were processed using Affymetrixt MAS 5.0 software, where we filtered for probe saturation, employed a global array scaling target intensity of 1000, and collected the signal intensity value (i.e., the 'average difference') for each gene. Pairwise 'treatment vs control' comparisons were made employing CyberT (Baldi and Long, 2001 ), a Bayesian t-statistic algorithm derived for microarray analysis. We employed a window size of 101 and used a confidence value of 10 in our CyberT analysis. Significant changes in expression were determined by ranking the assigned Bayesian P-values and applying a false discovery rate correction (FDR ¼ 0.05) to account for multiple testing (Benjamini and Hochberg, 1995) .
Semiquantitative RT-PCR
To confirm the microarray data, relative transcript levels were analysed by semiquantitative RT-PCR. Total RNA (5 mg) was used in first-strand cDNA synthesis with Superscriptt II reverse transcriptase (Invitrogen). PCR reaction conditions were optimized for each gene product to determine the PCR cycle number of linear amplification for each primer set. The primer sets, cycling conditions, and cycle numbers used are indicated in Table 2 . All PCR reactions were in 50 ml total volume. For ISG15, IFI56, and IFI 9-27, a reaction was set up containing 100 nM of each primer, 1.0 mM dNTPs, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 50 mM KCl, 2.5 U Taq polymerase (Roche Applied Science, Indianapolis, IN, USA), and 2.0 ml cDNA. IFI 6-16 was amplified with 100 nM of each primer, 1.0 mM dNTPs, 1 Â expand high fidelity buffer (MgCl 2 ) (Roche Applied Science), 0.5 mM MgCl 2 , 10% DMSO, 2.0 U Taq polymerase, and 4.0 ml cDNA. Amplification of ISG12 was carried out with 100 nM of each primer, 1.0 mM dNTPs, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 50 mM KCl, 2.0 U Taq polymerase, and 4.0 ml cDNA. IRF-1 cDNA was amplified with 200 nM of each primer, 1.0 mM dNTPs, 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.0 mM MgCl 2 , 2.5 U Taq polymerase, and 2.0 ml cDNA. Reaction conditions for b-actin were 300 nM of each primer (sequences obtained from Invitrogen), 1.0 mM dNTPs, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 50 mM KCl, 2.5 U Taq polymerase, and 2.0 ml cDNA. Products were amplified with GeneAmp PCR Systems 2400 and 9700 (Applied Biosystems, Foster City, CA, USA). In all, 10 ml of PCR product was analysed by electrophoresis in 1.2-1.5% agarose (Invitrogen) gels containing ethidium bromide and visualized under UV light. All samples were performed in triplicate and normalized to b-actin control.
Band quantitation was done using Kodak 1Dt Image Analysis Software (Eastman Kodak, Rochester, NY, USA).
ChIP assay
ChIP was performed by published methods with some modifications (Yahata et al., 2001) . Preliminary experiments were run to determine optimal sonication and formaldehyde cross-linking time. Once optimized, cells were harvested, pelleted, and treated with 1% formaldehyde for 15 min to cross-link cellular proteins. Cells were then rinsed twice in ice cold PBS containing protease inhibitors, pelleted, and resuspended in Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl at pH 8.1, 1 Â protease inhibitor cocktail (4 mg/ml epibestatin hydrochloride, 2 mg/ml calpain inhibitor II, 2 mg/ml pepstatin A, 4 mg/ml mastoparan, 4 mg/ml leupeptin hydrochloride, 4 mg/ml aprotinin, 1 mM TPCK, 1 mM phenymethylsulfonyl fluoride, and 100 mM TLCK)). Samples were then sonicated 3 Â 15 s each with a 1 min incubation on ice in between pulses on a Branson sonifier model 250 at 50% duty and maximum mini probe power. A 20 ml aliquot of lysate was saved and used to determine the input DNA for each sample. Supernatants were diluted (1 : 10) in dilution buffer(1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl at pH 8.1, 1 Â protease inhibitor cocktail), and precleared with 2 mg of sheared salmon sperm DNA (Gibco), 20 ml normal human serum, and 45 ml of protein A-sepharose (50% slurry in 10 mM Tris-HCl at pH 8.1, 1.0 mM EDTA). To precleared chromatin, 10 ml of either anti-CBP (A22, 0 . In all, 30 ml of PCR product was analysed by electrophoresis in 1.5% agarose gels containing ethidium bromide and visualized under UV light using Kodak 1Dt Image Analysis Software. All reactions were performed in triplicate.
Western blotting
Preparation of cellular lysates and immunoblotting were performed as previously described (Seewaldt et al., 1997b (Seewaldt et al., , 1999b . For IRF-1 expression, the membrane was incubated with a 1 : 100 dilution of mouse anti-human IRF-1 (C-20, Santa Cruz Biotechnology). For CBP expression, the blocked membrane was incubated with a 1 : 200 dilution of the CBP antibody (C-20, Santa Cruz Biotechnology). For STAT1 expression the membrane was incubated with a 1 : 100 dilution of antibody to STAT1 (E-23, Santa Cruz Biotechnology). For STAT1 phosphoserine-727 detection the membrane was incubated with a 1 : 400 dilution of the Phospho-STAT1-Ser727 antibody (Cell Signaling Technology, Beverly, MA, USA). Loading control was provided by a 1 : 200 dilution of antibody to b-actin (I-19, Santa Cruz Biotechnology). The resulting film images were digitized and quantitated using Kodak 1Dt Image Analysis Software.
Suppression of IRF-1 with siRNA
Two double-stranded siRNA oligos were designed using Ambion Inc. software (Austin, TX, USA). Oligos were synthesized and annealed by Qiagen. IRF-1 #1 targets sequence: 5 0 -AAC TTT CGC TGT GCC ATG AAC-3 0 , and IRF-1 #4 targets sequence: 5 0 -AAG TGT GAG CGC CTT GGT ATG-3 0 . Control nonsilencing siRNA was provided by Qiagen. Early passage HMEC-E6 cells were transfected with IRF-1 #1 and #4 siRNAs (167-600 nM) and Cellfectint (Invitrogen). At 12 h after transfection, RNA was harvested using the Aurumt Total RNA kit (Bio-Rad Laboratories, Hercules, CA, USA) and protein was harvested as previously described (Seewaldt et al., 1997b (Seewaldt et al., , 1999a . Western analysis (as described above) and RT-PCR were performed to confirm suppression of IRF-1 expression. cDNA was prepared for RT-PCR from 50 ng total RNA with Superscriptt II reverse transcriptase (Invitrogen). b-actin PCR reaction conditions were performed as described above except product was amplified for 24 cycles. IRF-1 amplification was reoptimized for lower input. The changes made to the reaction were as follows: (1) HotStarTaqt polymerase (Qiagen) was used, (2) annealing temperature was increased to 571C, and (3) amplification was carried out for 38 cycles. In all, 25 ml of PCR product was ran on either 2.0% or 1.2% agarose gels stained with ethidium bromide and visualized with Kodak 1Dt Image Analysis Software.
ELISA
Aliquots of tissue culture media were withdrawn from flasks at 0, 30 min, 1, 2, and 4 h and stored at À701C. Manufacturer protocols for the commercial IFN-a, -b (Biosource International, Camarillo, CA, USA), and IFN-g (BD Biosciences Pharmingen, San Diego, CA, USA) ELISA kits were followed. Duplicate standard curves were run on each plate, and media samples were assayed in triplicate.
IRF-1 promoter immunoprecipitation
HMEC-E6 cells and HMEC-LX controls were treated with 1.0 mM Tam and harvested at 0, 30, and 60 min. Preparation of cellular lysates and immunoblotting were performed as previously described (Seewaldt et al., 1997b (Seewaldt et al., , 1999b . A 25 bp section of the IRF-1 promoter region, encompassing the GAS element (À134 to À109 bp upstream), was used to design biotin-labeled oligos. The complimentary oligos (Qiagen) were annealed in equal molar concentrations, heated to 951C for 5 min, and allowed to cool to room temperature. Then 890 mg of total protein lysate was precleared with Strepavidin beads. The supernatant was subsequently incubated with IRF-1 GAS-annealed oligos and Strepavidin beads for 2 h at 41C. The beads were washed 3 Â with lysis buffer with protease inhibitors, boiled, and ran on an SDS-PAGE gel. Antibodies to CBP (C-20, Santa Cruz Biotechnology) and STAT1 (E-23, Santa Cruz Biotechnology) were used to detect bound protein.
Measurement of apoptosis and caspase-1/3 activity Apoptosis was measured by Annexin V binding and FACS after treatment with 1.0 mM Tam for 18 h as previously described (Seewaldt et al., 1999a; Dietze et al., 2001) . Caspase-1/3 assays were performed as follows: cells were harvested by trypsinization, washed once with 100 volumes of ice cold PBS, and pelleted. Caspase-1 and -3 activities were then assayed according to the manufacturer's instructions using a caspase-1 (EMD Biosciences Inc.) or caspase-3 (Clontech, Palo Alto, CA, USA) assay kit. For IRF-1 suppression studies, early passage HMEC-E6 cells were transfected with IRF-1 siRNAs 12 h prior to treatment with 1.0 mM Tam. Caspase-1 and -3 levels were measured at 4 and 18 h, respectively, after Tam treatment.
